Cell & Gene Therapy Innovation · the Circle
The therapy
has moved.
What delivers. What sustains.
Who reaches the patient.
Hotel Palace Berlin · 10–11 February 2027
the Why
Four premises.
One room.
01
The science
is approved.
Cell and gene therapy has crossed from experimental to clinical. Multiple modalities are approved. The constraint now is not the biology — it is the system that delivers the biology to the patient.
02
The system
is not ready.
Manufacturing scalability, supply chain resilience, reimbursement architecture and regulatory coherence remain unsolved at the scale the field demands. The delay costs lives.
03
The decisions
are being made now.
Platform choices, CMC commitments, vector supply partnerships and market access strategy are being set by a small number of principals. Those decisions will define patient outcomes for a decade.
04
The format
is the work.
CGTI is closed. Invite-only. No audience, no broadcast, no performative Q&A. The conversation is structured around decisions, not presentations. The room is the mechanism.
The gap is not scientific.
It is systemic.
Approved therapies sit in manufacturing pipelines that cannot scale. Vector supply constraints delay trials. Reimbursement models do not reflect the value of curative interventions. These are decision problems, not science problems. CGTI is the room where those decisions are tested — by the principals who must make them.
The conversation at CGTI is structured around the decisions the field cannot defer. Not what could be done. What will be decided.
in the room.
the Room
Where the conversation
takes form.
The principals who shape cell and gene therapy at the level of science, operations and clinical delivery.
CGTI convenes CDOs, CMOs, heads of manufacturing, clinical operations leads and regulatory strategy principals. Not from every organisation — from the ones where the decisions are actually made.
The room
Closed. Invite-only. The chair is a practitioner, not a moderator. The structure is built for alignment, not performance.
View facultyVendors
Faculty
The leaders.
Advisory · Voices · Faculty announced in cadence with the programme.
Uwe Gottschalk
Operating Partner
Keensight Capital
Daria Donati
Chief Scientific Officer
Cytiva
Frederik Buysse
General Manager EU
Legend Biotech
Jesús Zurdo
Patient Advocate
ARA Biosciences
Adrienne Mendoza
Chief Operating Officer
BioBridge Global
Harsukh Parmar
Former SVP R&D
EMD Serono
Angel Lucio
Chief Executive Officer
Tetraneuron
Christina Salado Manzano
Director, Advanced Therapies
Alcura Health
Adam Inche
Chief Executive Officer
LentiTek
Nine advisory speakers. Hotel Palace Berlin, 10–11 February 2027.
in the room.
Where it convenes.
The room, across
the Circle.
Berlin · Singapore · London
Berlin 2027
the Room
the Conversation
in the room.
Hotel Palace Berlin
the Circle
The room
The organisations
in the room.
Confirmed organisations across cell therapy, gene therapy, vector manufacturing, CDMOs, regulatory and reimbursement. The wall reflects the room.
Company wall populated on receipt of confirmed delegate list. Rows of 6, white 1:1 tiles, institutional register.